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Introduction 
The incidence of ocular adnexal lymphoma is reported to be less 
than 10% in all extranodal lymphomas [1]. More than half of the 
cases of ocular adnexal lymphoma are mucosa-associated 
lymphoid tissue (MALT) lymphomas [2]. MALT lymphoma, first 
described in 1983 by Isaacson and Wright [3], is believed to have 
a tendency to remain localized to the primary site for a long time 
[4]. Therefore, local therapy has usually been applied for this 
disease [5, 6]. Among several treatments, radiotherapy has been 
generally considered the most effective for the localized disease 
[1, 4, 5, 7-10]. The objective of our study is to analyze the 
characteristics of primary ocular adnexal MALT lymphoma 
(POAML) including its natural history, behavior of progression, 
prognostic factors and treatment-related adverse effects.   
 
Materials and Methods 
Eighty-six patients with histologically proven stage I POAML 
treated with radiotherapy at National Cancer Center Hospital 
between 1990 and 2010 were retrospectively reviewed. Median 
age was 56 years (range,18-85 years). There were 49 male (57%) 
and 37 female (43%) patients. The pathological diagnosis of 
MALT lymphoma was established by biopsy or surgical resection 
sample. Staging work-ups included physical examination, 
complete blood counts, magnetic resonance imaging (MRI) or 
computed tomography (CT) of both orbits, CT of the neck, thorax, 
abdomen and pelvis, and bone marrow biopsy. Tumors classified 
as stage I in this study were unilateral or simultaneous bilateral 
diseases that did not have extraorbital extensions. Twelve patients 
had simultaneous bilateral lesions. These bilateral lesions were 
both treated by radiation therapy, and the total number of the eyes 
undergoing radiation as a primary therapy was 98. Additionally, 
all the 6 relapses in the contralateral eyes underwent radiation 
therapy. Therefore, the total number of eyes treated by radiation 
was 104 (unilateral primary:74, bilateral pimary:12×2, 
contralateral relapses:6). As for subsites of the 104 eyes, 
conjunctiva and eyelid involvement was seen in 46 eyes, lacrimal 
gland was 7 and non-conjunctival/eyelid/lacrimal gland 
involvement in 51 eyes. 
The total of 77 patients including 66 of unilateral and 11 of 
bilateral lesions were treated by radiotherapy alone (Table 1). 
Among unilateral tumors, 3 patients received chemotherapy 
followed by radiotherapy, and other 5 patients underwent surgery 
(maximal excision) before radiation. Also, one of bilateral tumors 
was treated with radiation and chemotherapy. Among those 
treated with radiation and chemotherapy, 2 patients had four or six 
cycles of CHOP (cyclophosphamide, hydroxydaunorubicin, 
oncovin, and prednine), and 1 patient had four cycles of R-CHOP 
(rituximab + CHOP) and 1 patient had one cycle of COP 
(cyclophosphamide, oncovin, and prednine). Total of 4 patients 
received chemotherapy. 
The radiation dose varied between 30-46Gy in a conventional 
fractionation, and the median dose was 30Gy. No eyes were 
treated by dose lower than 30 Gy. Direct appositional electron 
irradiation with 3-12MeV was used in 41 eyes. The remaining 63 
eyes were treated with 4 or 6 MV photon beams with a single 
anterior field or a wedged pair of anterior and oblique fields. A 
lens block was used in 39 of 104 eyes (photon beam:27, electron 
beam:12), and a bolus was used in 41of 104 eyes (photon 
beam:13,electron beam:28). 
Local relapse free survival (LRFS) was calculated from the last 
day of radiotherapy until the date of the first documented relapse 
with death and last follow-up without local relapse considered as 
censored. Contralateral relapse-free survival (CRFS) was defined 
as time period from the last day of radiation therapy until the date 
of the first documented contralateral relapse with death and last 
follow-up without contralateral relapse considered as censored. In 
the analysis of contralateral relapses, 24 eyes of simultaneous 
bilateral diseases were not included, because there was no 
contralateral eye for primary bilateral lesions. Overall survival 
was defined as time period from the first day of radiotherapy until 
the date of death due to any cause or until the date of the last 
follow-up for patients who were alive. Cataract incidence was 
calculated from the last day of radiotherapy to the date of cataract 
diagnosis. All survival curves as well as the cataract incidence 
were calculated by the Kaplan-Meier method with a statistical 
difference tested by log-rank test. A p value of less than 0.05 was 
considered as statistically significant. All the statistical analyses 
were performed using Predictive Analytic Software (PASW), 
version 18.0 (SPSS Inc., Chicago, IL, USA). 
  
 
Results 
The median follow-up duration of all patients was 9 years (range, 
0.9-22 years).The 5- and 10-year OS rates were 97.6% and 93.5%, 
respectively (Fig.1). Also, the 5- and 10-year LRFS rates were 
Table 1 . Patient characteristics
Characteristics Number
Sex
Male 49patients (57%)
Female 37patients (43%)
Age
median/range 56/18-85years
Bilateral Presentation 12patients
Contralateral relapse 6patients
No. of Irradiated Eyes 104eyes
Unilateral Involvement 74eyes
Bilateral Involvement 24eyes
Contralateral relapse 6eyes
Primary Site　
conjunctiva and eyelid 46 eyes
lacrimal gland 7 eyes
non-conjunctiva/eyelid/lacrimal gland 51 eyes
Treatment　RT only/Chemo＋RT/Surg + RT 94/5/5eyes
Radiation Dose
median/range 30/30-46Gy
Treatment (Total number of treated eyes: 104)
X-ray 63eyes
Electron beam 41eyes
Shield
yes/no 39/65eyes
Bolus
yes/no 41 (photon beam:13, electron beam:28)/63eyes
98.7% and 98.7%, and CRFS rates were 97.0% and 90.8%, 
respectively. None died of the disease; the deaths of 6 patients 
were from non-lymphoma-related causes. The number of total 
relapses was10. Among them, one case relapsed locally in the 
irradiated eye, while contralateral relapses were seen in 6 patients. 
The other 3 patients had a distant relapse. The patient who 
developed local relapse had had simultaneous bilateral tumors at 
the presentation and both tumors were treated by radiation therapy. 
Only her right eye lymphoma in the conjunctiva relapsed 45 
months after electron beam irradiation of 30Gy. The 6 
contralateral relapses were also treated by radiation therapy alone, 
and all those lesions were controlled with a follow-up length of 3 
to 12 years. Patients with tumor size≧4cm showed a greater risk 
of contralateral relapses with 5- and 10-year CRFSs of 100% and 
55.6%, respectively, for the tumors≧ 4 cm, and 96.7% and 
94.3%, respectively, for the tumors < 4 cm (p=0.012) (Fig.2). 
Other factors, such as gender, age, tumor location were not 
significant for relapse in the contralateral orbit. 
 Fig.1. Overall survival(n = 86), local relapse free survival (n = 104), and contralateral 
relapse-free survival (n = 74) in patients with primary ocular adnexal MALT lymphoma 
(5- and 10-year OS rates: 97.6% and 93.5%,LRFS rates: 98.7% and 98.7%, and CRFS 
rates: 97.0% and 90.8%, respectively) 
 Fig. 2. Contralateral relapse free survival rates according to tumor sizes 
 
 
The clinical characteristics of simultaneous bilateral lesions are 
shown in Table 2. No clinical factors affected bilateral lesions 
except for tumor size. Bilateral lesions were seen in 6.9% of the 
patients with tumors larger than or equal to 1 cm, while in 28.6% 
of the patients with tumors less than 1 cm. (p = 0.007) 
  
Among patients who developed distant relapses, initial therapy 
was radiation alone for two patients, and surgery followed by 
radiation for one patient. Of those, two relapsed at mediastinum, 
and one relapsed at left pleura. All of them underwent additional 
treatment. One patient with mediastinum was treated with 6 
cycles of R-CHOP, and another patient with mediastinum 
underwent 6 cycles of R-CHOP followed by 30Gy of radiation. 
The patient with pleural disease underwent surgery. All the 
patients achieved CR and no evidence of disease at additional 
24-132 months of follow-up. There were no statistically 
Table 2. Clinical features of unilateral and bilateral lesions.
Unilateral Bilateral P value
Age 53.8 50.7 p=0.51
Gender
Male 42 7
Female 32 5
Size
<1cm 20 8
≧1cm 54 4
Location
Conjunctiva 30 8
Other than conjunctiva 44 4
p=0.919
p=0.007
p=0.091
significant influencing prognostic factors for distant relapse 
(Table 3). 
 
 
Risk factors for cataract were retrospectively evaluated in 104 
eyes including eyes treated for the primary diseases and 6 eyes 
treated for the contralateral relapse. Cataracts occurred in 48 of 
104 eyes. Of those, 31 eyes underwent surgery.  A lens-shielding 
technique was used in 39 of 104 eyes. Thirty-six of the 65 eyes 
without lens shielding developed a cataract with 5-year cataract 
incidence of 50.9%, whereas 12 of the 39 patients with lens 
shielding developed a cataract with 5-year cataract incidence of 
Table 3. Clinical features of distant metastasis.
Distant　relapse Others P value
Age 50.3 53.5 p=0.725
Gender
Male 2 47
Female 1 36
Size
<4cm 3 77
≧4cm 0 6
Location
Lacrimal gland 1 5
Other than lacrimal　gland 2 78
p=0.730
p=0.629
p=0.068
27.4% (p=0.037) (Fig.3). The radiation dose was not a risk factor 
(65 eyes were treated with 30Gy vs. 39 eyes were treated with 
>30Gy; p =0.843). Also, the use of a bolus did not influence upon 
risk of cataracts.  
 
Fig. 3. Cumulative incidence of cataract according to whether lens shielding was used 
 
Discussion 
In this study, excellent LRFS of  98.7% in 5 and 10 years was 
achieved, and moderate dose of 30 Gy was effective for stage I 
POAML [11-14].The predominant site of relapse was a 
contralateral orbit. However even those contralateral relapses 
were controlled well by radiation therapy alone. 
Most previous studies had analyzed the prognostic significance of 
tumor subsite at either a conjunctiva or other locations [1, 10, 15]. 
Some studies have suggested that tumor at conjunctival location 
may have a better prognosis than at other anatomic subsites of the 
orbit, while other studies did not find a difference between 
conjunctival location and other sites. In our study, we did not see 
any differences of prognosis between conjunctival and the other 
sites. Also, Nam stated that primary lacrimal involvement may be 
related to future relapse more frequently than other orbital 
subsites [16]. In our study, there were 6 patients with lacrimal 
primary. One patient had bilateral lacrimal involvements, and the 
total number of eyes with lacrimal involvement was 7 in 6 
patients. Among them, only one patient with lacrimal tumor 
developed a distant relapse 12 years after the radiation therapy. 
Because of the small number of the patients with distant relapse 
statistically significant influence of the primary orbital subsite 
upon distant relapse could not be seen.. 
 
Some reports of POAML showed distant relapse other than the 
ocular relapse, and the possible role of immunochemotherapy 
reducing the distant relapse was suggested. Hashimoto et al. 
reported that 30.6Gy combined with rituximab successfully 
decreased the risk of systemic relapse [14]. However, our study 
demonstrated after the extensive staging, distant relapse of stage I 
POAML is rare, and there seems to be only a small role of 
immunochemotherapy in stage I POAML. Additionally, most 
reported series have demonstrated excellent OS with only 
exceptional death due to POAML, delivering cost demanding 
immunochemotherapy in all patients with localized POAML is 
out of consideration. Contralateral orbital relapse was seen most 
often, but the median time to the contralateral relapse was as long 
as 84 months after radiation therapy. Therefore, patients with 
stage I POAML must be followed longer than 5 years with a 
meticulous attention to the contralateral eye. There are few 
reports on the management and prognosis of contralateral relapse 
of POAML. In our study, all the 6 contralateral relapses were 
treated by radiation therapy, and all were controlled for 3-12 years 
without local as well as extraorbital relapses. Goda et al. also 
stated that an isolated contralateral relapse of MALT lymphoma 
in the paired organ could be successfully managed with another 
course of RT and often did not result in further disease relapse in 
distant sites [17]. Solitary contralateral relapse of stage I POAML 
should be treated by repeated course of radiation therapy. 
Although anatomic site of tumor location, gender and age were 
not significant for relapse in the contralateral orbit, the patients 
with tumor size ≧ 4 cm showed a greater risk of contralateral 
relapse more than 5 years after the treatment. Therefore, long 
term follow-up is mandatory for patients with a larger tumor with 
attention to the contralateral eye.  
In our series, primary bilateral lesions were small in their size at 
the presentation. POAML often presents as a salmon-pink lesion 
that was sometimes misdiagnosed as other ocular surface diseases, 
such as allergic or chronic conjunctivitis, and it is sometimes 
challenging to recognize the small tumor [18].There is a 
possibility that patients with bilateral lesions might draw attention 
of the ophthalmologists to the symptoms including irritation, 
epiphora, and mass sensation compared to those with unilateral 
lesions. This might have resulted in an early diagnosis with 
relatively small size in our bilateral lesions. All of the bilateral 
lesions were controlled well by radiation except for one case of 
local relapse. Also, the NCCN Guidelines Version1.2013  
recommends [19] radiation therapy to both lesions in the bilateral 
POAML.   
Total dose of around 30 Gy in a conventional fractionation seems 
to be the present standard in radiotherapeutic management of 
POAML. Hashimoto reported that 30.6Gy combined with 
rituximab successfully decreased the risks of systemic relapse. In 
contrast, Tsang and coworkers reported that for local control of 
POAML results from the use of a slightly lower dose of 25Gy of 
30 patients in orbital lymphomas remained excellent [13]. 
Recently, low-dose radiation has become increasingly used in the 
management of indolent non-Hodgkin lymphoma (NHL) [20-25]. 
Fasola et al. recommended 2Gy ×2 as excellent treatment of NHL 
of the ocular adnexa for the purpose of disease control in patients 
with advanced stage with the option of reirradiation in the case of 
locoregional relapse [26] However, there are few data regarding 
how much the dose could be reduced safely in radical radiation 
therapy of POAML. Therefore, future clinical trials seem to be 
necessary to reduce the optimal deses in the radiation therapy for 
POAML.  
The employment of the shielding-block reduced the incidence of 
cataract with a statistically significant difference. However, 
because cataract was effectively managed by surgery with a 
resultant restoration of vision, shielding block must be inserted 
only in the lesions which would be treated with easy insertion of 
the shielding block.     
Conclusion  
Local radiation therapy up to 30 Gy can attain excellent local 
control and overall survival of POAML. Predominant site of 
relapse was a contralateral eye, which can be also controlled by 
local radiation. Because median time to contralateral relapse was 
84 months, long term follow-up of POAML is mandatory. 
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